At the sake of sounding clueless, I preface the following by acknowledging that I’m very green in trading and don’t have an in depth understanding of the world of biotech’s.
That said, having watched DCTH pretty closely over the last 6 months, my business sense tells me that the act of re-securing the full rights of the patents and technology was done in response to a condition that was probably baked into one of the toxic debt deals that expired at EOY, which would have essentially made Delcath worthless. Jenny and crew (my guess is mostly Simon) were able to figure things out in order to retain their IP by extinguishing the notes before the deadline, preserving the highest organizational value.
My hunch is that Pedder is on board, like many have stated, for the primary function of preparing DCTH to sell. Whether he stays on after the sale remains to be seen but I would think it’s likely we will see him in some sort of key role.
I believe that we will see the continued dumping until the MAXM’s, etc.. are empty or close to it. I doubt any buyer will want to fatten their pockets more than they absolutely have to. It sounds that DCTH has enough cash to run for a few months, or just as long as it takes for all the loan-shark shares to dry up. Then we’ll see our sale. And, while Jenny may be many things, she is smart enough to pull the kind of salary she does. That alone tells me she will be smart enough to structure herself a very nice transitional role in the process. She is likely being a princess and already knows where she’s landing after all of this.
All the above is purely just my rookie opinion. I invite thoughts, feedback or clarity, if I have misstated any information.
Cheers and GLTA!
